Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma

Concetta Quintarelli, Domenico Orlando, Iolanda Boffa, Marika Guercio, Vinicia Assunta Polito, Andrea Petretto, Chiara Lavarello, Matilde Sinibaldi, Gerrit Weber, Francesca Del Bufalo, Ezio Giorda, Marco Scarsella, Stefania Petrini, Daria Pagliara, Franco Locatelli, Biagio De Angelis, Ignazio Caruana

Research output: Contribution to journalArticle

Abstract

Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the treatment of B-cell malignancies. However, there are still substantial obstacles to overcome, before similar responses can be achieved in patients with solid tumors. We evaluated both in vitro and in a preclinical murine model the efficacy of different 2nd and 3rd generation CAR constructs targeting GD2, a disial-ganglioside expressed on the surface of neuroblastoma (NB) tumor cells. In order to address potential safety concerns regarding clinical application, an inducible safety switch, namely inducible Caspase-9 (iC9), was also included in the vector constructs. Our data indicate that a 3rd generation CAR incorporating CD28.4-1BB costimulatory domains is associated with improved anti-tumor efficacy as compared with a CAR incorporating the combination of CD28.OX40 domains. We demonstrate that the choice of 4-1BB signaling results into significant amelioration of several CAR T-cell characteristics, including: 1) T-cell exhaustion, 2) basal T-cell activation, 3) in vivo tumor control and 4) T-cell persistence. The fine-tuning of T-cell culture conditions obtained using IL7 and IL15 was found to be synergic with the CAR.GD2 design in increasing the anti-tumor activity of CAR T cells. We also demonstrate that activation of the suicide gene iC9, included in our construct without significantly impairing neither CAR expression nor anti-tumor activity, leads to a prompt induction of apoptosis of GD2.CAR T cells. Altogether, these findings are instrumental in optimizing the function of CAR T-cell products to be employed in the treatment of children with NB.

Original languageEnglish
Pages (from-to)e1433518
JournalOncoImmunology
Volume7
Issue number6
DOIs
Publication statusPublished - 2018

Fingerprint

Antigen Receptors
T-Cell Antigen Receptor
Neuroblastoma
Cytokines
Neoplasms
T-Lymphocytes
Caspase 9
Safety
Interleukin-15
Interleukin-7
Gangliosides
Cell- and Tissue-Based Therapy
Suicide
Transcriptional Activation
B-Lymphocytes
Cell Culture Techniques
Apoptosis
Therapeutics

Cite this

Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma. / Quintarelli, Concetta; Orlando, Domenico; Boffa, Iolanda; Guercio, Marika; Polito, Vinicia Assunta; Petretto, Andrea; Lavarello, Chiara; Sinibaldi, Matilde; Weber, Gerrit; Del Bufalo, Francesca; Giorda, Ezio; Scarsella, Marco; Petrini, Stefania; Pagliara, Daria; Locatelli, Franco; De Angelis, Biagio; Caruana, Ignazio.

In: OncoImmunology, Vol. 7, No. 6, 2018, p. e1433518.

Research output: Contribution to journalArticle

@article{77e08d75a7d542139eb5c72b74a018a0,
title = "Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma",
abstract = "Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the treatment of B-cell malignancies. However, there are still substantial obstacles to overcome, before similar responses can be achieved in patients with solid tumors. We evaluated both in vitro and in a preclinical murine model the efficacy of different 2nd and 3rd generation CAR constructs targeting GD2, a disial-ganglioside expressed on the surface of neuroblastoma (NB) tumor cells. In order to address potential safety concerns regarding clinical application, an inducible safety switch, namely inducible Caspase-9 (iC9), was also included in the vector constructs. Our data indicate that a 3rd generation CAR incorporating CD28.4-1BB costimulatory domains is associated with improved anti-tumor efficacy as compared with a CAR incorporating the combination of CD28.OX40 domains. We demonstrate that the choice of 4-1BB signaling results into significant amelioration of several CAR T-cell characteristics, including: 1) T-cell exhaustion, 2) basal T-cell activation, 3) in vivo tumor control and 4) T-cell persistence. The fine-tuning of T-cell culture conditions obtained using IL7 and IL15 was found to be synergic with the CAR.GD2 design in increasing the anti-tumor activity of CAR T cells. We also demonstrate that activation of the suicide gene iC9, included in our construct without significantly impairing neither CAR expression nor anti-tumor activity, leads to a prompt induction of apoptosis of GD2.CAR T cells. Altogether, these findings are instrumental in optimizing the function of CAR T-cell products to be employed in the treatment of children with NB.",
author = "Concetta Quintarelli and Domenico Orlando and Iolanda Boffa and Marika Guercio and Polito, {Vinicia Assunta} and Andrea Petretto and Chiara Lavarello and Matilde Sinibaldi and Gerrit Weber and {Del Bufalo}, Francesca and Ezio Giorda and Marco Scarsella and Stefania Petrini and Daria Pagliara and Franco Locatelli and {De Angelis}, Biagio and Ignazio Caruana",
year = "2018",
doi = "10.1080/2162402X.2018.1433518",
language = "English",
volume = "7",
pages = "e1433518",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Taylor and Francis Inc.",
number = "6",

}

TY - JOUR

T1 - Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma

AU - Quintarelli, Concetta

AU - Orlando, Domenico

AU - Boffa, Iolanda

AU - Guercio, Marika

AU - Polito, Vinicia Assunta

AU - Petretto, Andrea

AU - Lavarello, Chiara

AU - Sinibaldi, Matilde

AU - Weber, Gerrit

AU - Del Bufalo, Francesca

AU - Giorda, Ezio

AU - Scarsella, Marco

AU - Petrini, Stefania

AU - Pagliara, Daria

AU - Locatelli, Franco

AU - De Angelis, Biagio

AU - Caruana, Ignazio

PY - 2018

Y1 - 2018

N2 - Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the treatment of B-cell malignancies. However, there are still substantial obstacles to overcome, before similar responses can be achieved in patients with solid tumors. We evaluated both in vitro and in a preclinical murine model the efficacy of different 2nd and 3rd generation CAR constructs targeting GD2, a disial-ganglioside expressed on the surface of neuroblastoma (NB) tumor cells. In order to address potential safety concerns regarding clinical application, an inducible safety switch, namely inducible Caspase-9 (iC9), was also included in the vector constructs. Our data indicate that a 3rd generation CAR incorporating CD28.4-1BB costimulatory domains is associated with improved anti-tumor efficacy as compared with a CAR incorporating the combination of CD28.OX40 domains. We demonstrate that the choice of 4-1BB signaling results into significant amelioration of several CAR T-cell characteristics, including: 1) T-cell exhaustion, 2) basal T-cell activation, 3) in vivo tumor control and 4) T-cell persistence. The fine-tuning of T-cell culture conditions obtained using IL7 and IL15 was found to be synergic with the CAR.GD2 design in increasing the anti-tumor activity of CAR T cells. We also demonstrate that activation of the suicide gene iC9, included in our construct without significantly impairing neither CAR expression nor anti-tumor activity, leads to a prompt induction of apoptosis of GD2.CAR T cells. Altogether, these findings are instrumental in optimizing the function of CAR T-cell products to be employed in the treatment of children with NB.

AB - Chimeric antigen receptor (CAR) T-cell therapy has been shown to be dramatically effective in the treatment of B-cell malignancies. However, there are still substantial obstacles to overcome, before similar responses can be achieved in patients with solid tumors. We evaluated both in vitro and in a preclinical murine model the efficacy of different 2nd and 3rd generation CAR constructs targeting GD2, a disial-ganglioside expressed on the surface of neuroblastoma (NB) tumor cells. In order to address potential safety concerns regarding clinical application, an inducible safety switch, namely inducible Caspase-9 (iC9), was also included in the vector constructs. Our data indicate that a 3rd generation CAR incorporating CD28.4-1BB costimulatory domains is associated with improved anti-tumor efficacy as compared with a CAR incorporating the combination of CD28.OX40 domains. We demonstrate that the choice of 4-1BB signaling results into significant amelioration of several CAR T-cell characteristics, including: 1) T-cell exhaustion, 2) basal T-cell activation, 3) in vivo tumor control and 4) T-cell persistence. The fine-tuning of T-cell culture conditions obtained using IL7 and IL15 was found to be synergic with the CAR.GD2 design in increasing the anti-tumor activity of CAR T cells. We also demonstrate that activation of the suicide gene iC9, included in our construct without significantly impairing neither CAR expression nor anti-tumor activity, leads to a prompt induction of apoptosis of GD2.CAR T cells. Altogether, these findings are instrumental in optimizing the function of CAR T-cell products to be employed in the treatment of children with NB.

U2 - 10.1080/2162402X.2018.1433518

DO - 10.1080/2162402X.2018.1433518

M3 - Article

C2 - 29872565

VL - 7

SP - e1433518

JO - OncoImmunology

JF - OncoImmunology

SN - 2162-4011

IS - 6

ER -